Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer
Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer globally. Diagnosis of advanced non-small cell lung cancer (NSCLC) is associated with 5-year relative survival of 3.2%. ROS proto-oncogene 1 (ROS1) is an oncogenic driver of NSCLC occurring in up to 2% o...
Gespeichert in:
| Veröffentlicht in: | Pathology 2019-12, Vol.51 (7), p.673-680 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 680 |
|---|---|
| container_issue | 7 |
| container_start_page | 673 |
| container_title | Pathology |
| container_volume | 51 |
| creator | Pavlakis, Nick Cooper, Caroline John, Thomas Kao, Steven Klebe, Sonja Lee, Chee Khoon Leong, Trishe Millward, Michael O'Byrne, Ken Russell, Prudence A. Solomon, Benjamin Cooper, Wendy A. Fox, Stephen |
| description | Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer globally. Diagnosis of advanced non-small cell lung cancer (NSCLC) is associated with 5-year relative survival of 3.2%. ROS proto-oncogene 1 (ROS1) is an oncogenic driver of NSCLC occurring in up to 2% of cases and commonly associated with younger age and a history of never or light smoking. Results of an early trial with the tyrosine kinase inhibitor (TKI) crizotinib that inhibits tumours that harbour ROS1 rearrangements have shown an objective response rate (ORR) of 72% (95% CI 58–83%), median progression free survival (PFS) of 19.3 months (95% CI 15.2–39.1 months) and median overall survival (OS) of 51.4 months (95% CI 29.3 months to not reached). Therefore, with the availability of highly effective ROS1-targeted TKI therapy, upfront molecular testing for ROS1 status alongside EGFR and ALK testing is recommended for all patients with NSCLC. We review the tissue requirements for ROS1 testing by immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) and we present a testing algorithm for advanced NSCLC and consider how the future of pathology testing for ROS1 may evolve. |
| doi_str_mv | 10.1016/j.pathol.2019.08.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2310723044</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0031302519303800</els_id><sourcerecordid>2310723044</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-4c7032a045fcba802b6be2c6898d9f458dc8a8f82f04877636e99c6f2b0563a73</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaDZp_0EpOuZiZ_RhWb4UQkibwEIgbc9ClsetFlveSnKg_74ym-bYywzMvDPvzEPIRwY1A6auD_XR5l_LVHNgXQ26BlBvyI5J1VSiE-wt2QEIVgngzTm5SOkAAFJr_Y6cC6aUlqB2ZLhZU4528jZQt4SEIa2JpmwzzhgyHZdIe0yZHqN12TukT4_fGM2l5MNP6gO1w7MNDgcallCl2U4TdVjCtJa-21rxPTkb7ZTww0u-JD--3H2_va_2j18fbm_2lROK50q6FgS3IJvR9VYD71WP3Cnd6aEbZaMHp60eNR_LH22rhMKuc2rkPTRK2FZckqvT3mNcfq_lRDP7tB1jAy5rMlwwaLkAKYtUnqQuLilFHM0x-tnGP4aB2fiagznxNRtfA9oUvmXs04vD2s84vA79A1oEn08CLH8-e4wmOY8bHx_RZTMs_v8OfwGI_Y5L</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2310723044</pqid></control><display><type>article</type><title>Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Pavlakis, Nick ; Cooper, Caroline ; John, Thomas ; Kao, Steven ; Klebe, Sonja ; Lee, Chee Khoon ; Leong, Trishe ; Millward, Michael ; O'Byrne, Ken ; Russell, Prudence A. ; Solomon, Benjamin ; Cooper, Wendy A. ; Fox, Stephen</creator><creatorcontrib>Pavlakis, Nick ; Cooper, Caroline ; John, Thomas ; Kao, Steven ; Klebe, Sonja ; Lee, Chee Khoon ; Leong, Trishe ; Millward, Michael ; O'Byrne, Ken ; Russell, Prudence A. ; Solomon, Benjamin ; Cooper, Wendy A. ; Fox, Stephen</creatorcontrib><description>Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer globally. Diagnosis of advanced non-small cell lung cancer (NSCLC) is associated with 5-year relative survival of 3.2%. ROS proto-oncogene 1 (ROS1) is an oncogenic driver of NSCLC occurring in up to 2% of cases and commonly associated with younger age and a history of never or light smoking. Results of an early trial with the tyrosine kinase inhibitor (TKI) crizotinib that inhibits tumours that harbour ROS1 rearrangements have shown an objective response rate (ORR) of 72% (95% CI 58–83%), median progression free survival (PFS) of 19.3 months (95% CI 15.2–39.1 months) and median overall survival (OS) of 51.4 months (95% CI 29.3 months to not reached). Therefore, with the availability of highly effective ROS1-targeted TKI therapy, upfront molecular testing for ROS1 status alongside EGFR and ALK testing is recommended for all patients with NSCLC. We review the tissue requirements for ROS1 testing by immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) and we present a testing algorithm for advanced NSCLC and consider how the future of pathology testing for ROS1 may evolve.</description><identifier>ISSN: 0031-3025</identifier><identifier>EISSN: 1465-3931</identifier><identifier>DOI: 10.1016/j.pathol.2019.08.006</identifier><identifier>PMID: 31668406</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Australia ; biomarker testing ; Biomarkers - analysis ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - pathology ; consensus ; Crizotinib - pharmacology ; Gene Rearrangement ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Lung Neoplasms - diagnosis ; Lung Neoplasms - genetics ; Lung Neoplasms - pathology ; Non-small cell lung cancer ; Protein Kinase Inhibitors - pharmacology ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Protein-Tyrosine Kinases - genetics ; Protein-Tyrosine Kinases - metabolism ; Proto-Oncogene Proteins - antagonists & inhibitors ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins - metabolism ; ROS1</subject><ispartof>Pathology, 2019-12, Vol.51 (7), p.673-680</ispartof><rights>2019</rights><rights>Crown Copyright © 2019. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-4c7032a045fcba802b6be2c6898d9f458dc8a8f82f04877636e99c6f2b0563a73</citedby><cites>FETCH-LOGICAL-c362t-4c7032a045fcba802b6be2c6898d9f458dc8a8f82f04877636e99c6f2b0563a73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31668406$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pavlakis, Nick</creatorcontrib><creatorcontrib>Cooper, Caroline</creatorcontrib><creatorcontrib>John, Thomas</creatorcontrib><creatorcontrib>Kao, Steven</creatorcontrib><creatorcontrib>Klebe, Sonja</creatorcontrib><creatorcontrib>Lee, Chee Khoon</creatorcontrib><creatorcontrib>Leong, Trishe</creatorcontrib><creatorcontrib>Millward, Michael</creatorcontrib><creatorcontrib>O'Byrne, Ken</creatorcontrib><creatorcontrib>Russell, Prudence A.</creatorcontrib><creatorcontrib>Solomon, Benjamin</creatorcontrib><creatorcontrib>Cooper, Wendy A.</creatorcontrib><creatorcontrib>Fox, Stephen</creatorcontrib><title>Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer</title><title>Pathology</title><addtitle>Pathology</addtitle><description>Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer globally. Diagnosis of advanced non-small cell lung cancer (NSCLC) is associated with 5-year relative survival of 3.2%. ROS proto-oncogene 1 (ROS1) is an oncogenic driver of NSCLC occurring in up to 2% of cases and commonly associated with younger age and a history of never or light smoking. Results of an early trial with the tyrosine kinase inhibitor (TKI) crizotinib that inhibits tumours that harbour ROS1 rearrangements have shown an objective response rate (ORR) of 72% (95% CI 58–83%), median progression free survival (PFS) of 19.3 months (95% CI 15.2–39.1 months) and median overall survival (OS) of 51.4 months (95% CI 29.3 months to not reached). Therefore, with the availability of highly effective ROS1-targeted TKI therapy, upfront molecular testing for ROS1 status alongside EGFR and ALK testing is recommended for all patients with NSCLC. We review the tissue requirements for ROS1 testing by immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) and we present a testing algorithm for advanced NSCLC and consider how the future of pathology testing for ROS1 may evolve.</description><subject>Australia</subject><subject>biomarker testing</subject><subject>Biomarkers - analysis</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>consensus</subject><subject>Crizotinib - pharmacology</subject><subject>Gene Rearrangement</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - pathology</subject><subject>Non-small cell lung cancer</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Protein-Tyrosine Kinases - genetics</subject><subject>Protein-Tyrosine Kinases - metabolism</subject><subject>Proto-Oncogene Proteins - antagonists & inhibitors</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins - metabolism</subject><subject>ROS1</subject><issn>0031-3025</issn><issn>1465-3931</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1r3DAQhkVpaDZp_0EpOuZiZ_RhWb4UQkibwEIgbc9ClsetFlveSnKg_74ym-bYywzMvDPvzEPIRwY1A6auD_XR5l_LVHNgXQ26BlBvyI5J1VSiE-wt2QEIVgngzTm5SOkAAFJr_Y6cC6aUlqB2ZLhZU4528jZQt4SEIa2JpmwzzhgyHZdIe0yZHqN12TukT4_fGM2l5MNP6gO1w7MNDgcallCl2U4TdVjCtJa-21rxPTkb7ZTww0u-JD--3H2_va_2j18fbm_2lROK50q6FgS3IJvR9VYD71WP3Cnd6aEbZaMHp60eNR_LH22rhMKuc2rkPTRK2FZckqvT3mNcfq_lRDP7tB1jAy5rMlwwaLkAKYtUnqQuLilFHM0x-tnGP4aB2fiagznxNRtfA9oUvmXs04vD2s84vA79A1oEn08CLH8-e4wmOY8bHx_RZTMs_v8OfwGI_Y5L</recordid><startdate>201912</startdate><enddate>201912</enddate><creator>Pavlakis, Nick</creator><creator>Cooper, Caroline</creator><creator>John, Thomas</creator><creator>Kao, Steven</creator><creator>Klebe, Sonja</creator><creator>Lee, Chee Khoon</creator><creator>Leong, Trishe</creator><creator>Millward, Michael</creator><creator>O'Byrne, Ken</creator><creator>Russell, Prudence A.</creator><creator>Solomon, Benjamin</creator><creator>Cooper, Wendy A.</creator><creator>Fox, Stephen</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201912</creationdate><title>Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer</title><author>Pavlakis, Nick ; Cooper, Caroline ; John, Thomas ; Kao, Steven ; Klebe, Sonja ; Lee, Chee Khoon ; Leong, Trishe ; Millward, Michael ; O'Byrne, Ken ; Russell, Prudence A. ; Solomon, Benjamin ; Cooper, Wendy A. ; Fox, Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-4c7032a045fcba802b6be2c6898d9f458dc8a8f82f04877636e99c6f2b0563a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Australia</topic><topic>biomarker testing</topic><topic>Biomarkers - analysis</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>consensus</topic><topic>Crizotinib - pharmacology</topic><topic>Gene Rearrangement</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - pathology</topic><topic>Non-small cell lung cancer</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Protein-Tyrosine Kinases - genetics</topic><topic>Protein-Tyrosine Kinases - metabolism</topic><topic>Proto-Oncogene Proteins - antagonists & inhibitors</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins - metabolism</topic><topic>ROS1</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pavlakis, Nick</creatorcontrib><creatorcontrib>Cooper, Caroline</creatorcontrib><creatorcontrib>John, Thomas</creatorcontrib><creatorcontrib>Kao, Steven</creatorcontrib><creatorcontrib>Klebe, Sonja</creatorcontrib><creatorcontrib>Lee, Chee Khoon</creatorcontrib><creatorcontrib>Leong, Trishe</creatorcontrib><creatorcontrib>Millward, Michael</creatorcontrib><creatorcontrib>O'Byrne, Ken</creatorcontrib><creatorcontrib>Russell, Prudence A.</creatorcontrib><creatorcontrib>Solomon, Benjamin</creatorcontrib><creatorcontrib>Cooper, Wendy A.</creatorcontrib><creatorcontrib>Fox, Stephen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pavlakis, Nick</au><au>Cooper, Caroline</au><au>John, Thomas</au><au>Kao, Steven</au><au>Klebe, Sonja</au><au>Lee, Chee Khoon</au><au>Leong, Trishe</au><au>Millward, Michael</au><au>O'Byrne, Ken</au><au>Russell, Prudence A.</au><au>Solomon, Benjamin</au><au>Cooper, Wendy A.</au><au>Fox, Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer</atitle><jtitle>Pathology</jtitle><addtitle>Pathology</addtitle><date>2019-12</date><risdate>2019</risdate><volume>51</volume><issue>7</issue><spage>673</spage><epage>680</epage><pages>673-680</pages><issn>0031-3025</issn><eissn>1465-3931</eissn><abstract>Lung cancer is the most commonly diagnosed malignancy and the leading cause of death from cancer globally. Diagnosis of advanced non-small cell lung cancer (NSCLC) is associated with 5-year relative survival of 3.2%. ROS proto-oncogene 1 (ROS1) is an oncogenic driver of NSCLC occurring in up to 2% of cases and commonly associated with younger age and a history of never or light smoking. Results of an early trial with the tyrosine kinase inhibitor (TKI) crizotinib that inhibits tumours that harbour ROS1 rearrangements have shown an objective response rate (ORR) of 72% (95% CI 58–83%), median progression free survival (PFS) of 19.3 months (95% CI 15.2–39.1 months) and median overall survival (OS) of 51.4 months (95% CI 29.3 months to not reached). Therefore, with the availability of highly effective ROS1-targeted TKI therapy, upfront molecular testing for ROS1 status alongside EGFR and ALK testing is recommended for all patients with NSCLC. We review the tissue requirements for ROS1 testing by immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) and we present a testing algorithm for advanced NSCLC and consider how the future of pathology testing for ROS1 may evolve.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>31668406</pmid><doi>10.1016/j.pathol.2019.08.006</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-3025 |
| ispartof | Pathology, 2019-12, Vol.51 (7), p.673-680 |
| issn | 0031-3025 1465-3931 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2310723044 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Australia biomarker testing Biomarkers - analysis Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology consensus Crizotinib - pharmacology Gene Rearrangement Humans Immunohistochemistry In Situ Hybridization, Fluorescence Lung Neoplasms - diagnosis Lung Neoplasms - genetics Lung Neoplasms - pathology Non-small cell lung cancer Protein Kinase Inhibitors - pharmacology Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism Proto-Oncogene Proteins - antagonists & inhibitors Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins - metabolism ROS1 |
| title | Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T09%3A49%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Australian%20consensus%20statement%20for%20best%20practice%20ROS1%20testing%20in%20advanced%20non-small%20cell%20lung%20cancer&rft.jtitle=Pathology&rft.au=Pavlakis,%20Nick&rft.date=2019-12&rft.volume=51&rft.issue=7&rft.spage=673&rft.epage=680&rft.pages=673-680&rft.issn=0031-3025&rft.eissn=1465-3931&rft_id=info:doi/10.1016/j.pathol.2019.08.006&rft_dat=%3Cproquest_cross%3E2310723044%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2310723044&rft_id=info:pmid/31668406&rft_els_id=S0031302519303800&rfr_iscdi=true |